Soleus Private Equity Fund III L.P. 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 3:30 pm Sale | 2024-09-30 | 13G | Mereo BioPharma Group plc MREO | Soleus Private Equity Fund III L.P. | 4,234,765 0.500% | -44,652,330 (-91.34%) | Filing |
| 2024-02-06 4:15 pm Purchase | 2023-12-31 | 13G | Mereo BioPharma Group plc MREO | Soleus Private Equity Fund III L.P. | 48,887,095 7.000% | 500,000 (+1.03%) | Filing |
| 2023-07-26 4:31 pm Purchase | 2023-07-24 | 13G | Mereo BioPharma Group plc MREO | Soleus Private Equity Fund III L.P. | 48,387,095 7.500% | 48,387,095 (New Position) | Filing |